at was a long ride some 10 years but they are a complete failure with the presentation and product
I would sell at this point
there is nothing left here to save but the few pennies left in the stock
how can the panel approve anything when the FDA has stated dcth needs a new trial?
At best they will get a refuse to accept the application to approve the device. has anyone thought this through?
what can the panel review? all we have is gen 1 trial data. we are back to square 1.
dcth has to raise more cash and start all over again.
I see this going much lower as the stock gets diluted with new massive stock offerings.
I sold and lost money lucky to be out at a $1
these guys have been doing this for 25 years and that is a quarter century missing the mark
you have to be nuts to invest in deathcath at this point
hepatic progression free survival (hPFS), the BAC-cross over arm of the study was consistent with the hPFS achieved in patients randomized directly to the chemosaturation arm. Furthermore, the study showed that crossover from BAC to the chemosaturation arm led to a median overall survival benefit of 11 months compared to treatment with BAC alone.